Biogen (NASDAQ:BIIB - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.
BIIB has been the subject of several other research reports. Needham & Company LLC restated a "buy" rating on shares of Biogen in a report on Wednesday. Barclays boosted their price target on shares of Biogen from $200.00 to $230.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 28th. UBS Group raised their price objective on Biogen from $270.00 to $300.00 and gave the company a "buy" rating in a report on Thursday, October 29th. Oppenheimer reiterated an "outperform" rating and issued a $300.00 price target on shares of Biogen in a research note on Wednesday, July 29th. Finally, HSBC boosted their target price on Biogen from $165.00 to $175.00 and gave the stock a "reduce" rating in a report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $255.45.
View Our Latest Report on Biogen
Biogen Stock Up 1.0%
NASDAQ:BIIB opened at $249.59 on Friday. The stock's fifty day moving average price is $236.83 and its two-hundred day moving average price is $206.86. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95. The company has a market cap of $36.89 billion, a price-to-earnings ratio of 106.66, a P/E/G ratio of 2.83 and a beta of 0.10. Biogen has a 52-week low of $160.36 and a 52-week high of $261.00.
Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The company had revenue of $2.80 billion during the quarter, compared to analysts' expectations of $2.63 billion. During the same quarter in the previous year, the company earned $4.81 EPS. Biogen's revenue was up 10.6% on a year-over-year basis. On average, analysts anticipate that Biogen will post 12.46 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Align Financial LLC lifted its position in shares of Biogen by 339.3% during the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company's stock worth $28,000 after buying an additional 95 shares during the last quarter. Bell Investment Advisors Inc bought a new position in shares of Biogen in the second quarter worth about $27,000. Provenance Wealth Advisors LLC acquired a new stake in shares of Biogen in the 3rd quarter valued at approximately $29,000. Canton Hathaway LLC acquired a new stake in shares of Biogen in the 3rd quarter valued at approximately $31,000. Finally, Financial Freedom LLC bought a new stake in shares of Biogen during the 3rd quarter valued at approximately $34,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.
Biogen News Summary
These are some of the BIIB news items that stood out recently:
- Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with α-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
- Positive Sentiment: Coverage also highlighted three-year real-world LEQEMBI data reporting slower Alzheimer’s progression, another potential support for the drug’s commercial prospects. Article
- Positive Sentiment: A new research collaboration with TRIMTECH will explore protein-degrader approaches for neurodegenerative diseases, offering possible longer-term pipeline potential, though it remains early-stage research. Article
About Biogen
(
Get Free Report)
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.